Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies

Olverembatinib approved for commercialization in Macau China

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program

Biostar Pharma gets FDA clearance of the IND application for a Phase 2 study of Utidelone Injection

Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux

Ligand to acquire Apeiron Biologics for US$100 million

Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.

LG Chem enters Chinese osteoarthritis treatment market

Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China

Merck and Orion announce option providing Merck global exclusive rights to Opevesostat

An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer

Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

Venus Remedies clinches WHO-backed PAHO tender

The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types